Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$15.45 USD
+0.26 (1.71%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $15.43 -0.02 (-0.13%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth C Momentum A VGM
Price, Consensus and EPS Surprise
CPRX 15.45 +0.26(1.71%)
Will CPRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CPRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CPRX
Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?
Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues
CPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?
ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store?
Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?
Other News for CPRX
Catalyst Pharmaceuticals (NASDAQ:CPRX): A Growth-Oriented Value Investment Opportunity
Insider Sale: Chief Commercial Officer Carmen Del Sells Shares of Catalyst Pharmaceuticals Inc ...
Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), Ventyx Biosciences (VTYX) and Catalyst Pharma (CPRX)
A Closer Look at 7 Analyst Recommendations For Catalyst Pharmaceuticals
Firdapse’s Enhanced Growth Prospects and Catalyst Pharma’s Market Expansion Secure Buy Rating